The Pharma Letter41m
EC approves CSL and Arcturus’ Kostaive
The European Commission has granted marketing authorization for Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, ...
The Pharma Letter21h
DMD market set for strong growth in coming years
The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across ...
The Pharma Letter21h
SinoCellTech gains China approval for finotonlimab
SinoCellTech (SHA: 688520) has received regulatory approval in China for finotonlimab, making it the first immuno-oncology ...
The Pharma Letter23h
Kerendia: Bayer’s big opportunity to deliver for millions of patients, across indications
An interview with Bayer's Bernardo Kanahuati, senior vice president, global head cardiorenal and product team lead, Kerendia, and Katja Rohwedder, senior medical affairs physician, global medical ...
The Pharma Letter23h
Bristol Myers’ Phase III Opdualag trial misses goal
Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...